ClinicalTrials.gg
CompletedNCT01358266SAKURAUpdated Jul 16, 2019Results posted

Study Assessing Double-masked Uveitis Treatment

A Phase 3 interventional study of DE-109 44 ug and DE-109 440 ug in Uveitis; Posterior, Disorder, sponsored by Santen Inc.. Completed at 151 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-16.

Sponsored by Santen Inc. (part of Santen Pharmaceutical Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
592
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 139 studies in Uveitis with a site in United States — 7 open to participants now, 11 under way, 1 of them phase 3. Uveitis · United States.

Enrollment
Largest of 100
592 · median 19
Started
2011
with 6 others
Phase 3
31 of 139
none open now
Registered
72nd of 139
by date

Among the 139 studies in Uveitis with a site in United States, this one has the largest enrollment of the 100 interventional ones that give a count, is one of 7 that started in 2011, is one of 31 in phase 3, and was the 72nd registered.

Uveitis

300 studies on the registry are indexed under Uveitis; 33 are open to participants now.

Browse Uveitis studies →

Open to participants now

7 of the 139 studies in Uveitis with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 22 Uveitis studies recruiting now, 13 (59%) set no upper age limit and 9 (41%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Uveitis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of intravitreal injections of DE-109 ophthalmic solution.

03

Conditions studied

  • Uveitis; Posterior, Disorder

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of active uveitis
  • 18 years of age or older
  • Sign
  • Meet best corrected ETDRS visual acuity

Exclusion criteria

Exclusion Criteria:

  • Uveitis of infectious etiology
  • Suspected/confirmed central nervous system or ocular lymphoma
  • Primary diagnosis of anterior uveitis
  • Uncontrolled glaucoma
  • Use of topical oculary medication
  • Implanted device
  • Significant ocular disease
  • Lens/media opacities or obscured ocular media
  • Intraocular surgery or treatments
  • Capsulotomy
  • Ocular or periocular infection
  • Pupillary dilation
  • History of herpetic infection
  • Toxoplasmosis or toxoplasmosis scar
  • Ocular
  • Allergy or to study drug
  • Participation in other uveitis trial within 30 days
  • Monoclonal antibody treatment or biologic therapy
  • Any systemic condition/infection
  • therapy or immunocompromised
  • Malignancy remission
  • Females who are pregnant or lactating and females not using adequate
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
592 participants (actual)

Study arms

  • Active comparator
    Ophthalmic solution low dose

    Drug: DE-109 44 ug

  • Active comparator
    Ophthalmic solution medium dose

    Drug: DE-109 440 ug

  • Active comparator
    Ophthalmic solution high dose

    Drug: DE-109 880 ug

Interventions

06

What researchers measure

Primary outcomes

  1. The Primary Endpoint, VH 0 Response, Was Defined as Having a VH Score of 0 at Month 5

    At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Description VH score 0 = No inflammation

    Time frame: Day1 (Baseline) and Month 5 (Day150)

Secondary outcomes

  1. VH 0 or 2-unit Response: Having a Reduction (Improvement) of at Least 2 Units From Baseline in VH Score or a VH Score of 0 at Month 5 (Modified SUN Scale)

    At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Step Description 0 No inflammation 0.5+ Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex) 1. Mild blurring of the retinal vessels and optic nerve 1.5+ Optic nerve head and posterior retina view obstruction greater than 1+ but less than 2+ 2. Moderate blurring of the optic nerve head 3. Marked blurring of the optic nerve head 4. Optic Nerve head not visible

    Time frame: Day1/Baseline and Day150/Month 5

  2. VH 0 or 0.5+ Response: Having a VH Score of 0 or 0.5+ at Month 5 (Modified SUN Scale)

    At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Description VH score 0.5+=Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex)

    Time frame: Day1/Baseline and Day150/Month 5

Other outcomes

  1. VH 0 Response at Month 6: Having a VH Score of 0 at Month 6 (Modified SUN Scale)

    At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Description VH score 0 = No inflammation

    Time frame: Day1/Baseline and Day180/Month 6

  2. VH 0 or 2-unit Response at Month 6: Having a VH Score of 0 or a Decrease (Improvement) of at Least 2 Units From Baseline in VH Score at Month 6 (Modified SUN Scale)

    At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Step Description 0 No inflammation 0.5+ Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex) 1. Mild blurring of the retinal vessels and optic nerve 1.5+ Optic nerve head and posterior retina view obstruction greater than 1+ but less than 2+ 2. Moderate blurring of the optic nerve head 3. Marked blurring of the optic nerve head 4. Optic Nerve head not visible

    Time frame: Day1/Baseline and Day180/Month 6

  3. VH 0 or 0.5+ Response at Month 6: Having a VH Score of 0 or 0.5+ at Month 6 (Modified SUNscale)

    At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Step Description 0 No inflammation 0.5+ Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex) 1. Mild blurring of the retinal vessels and optic nerve 1.5+ Optic nerve head and posterior retina view obstruction greater than 1+ but less than 2+ 2. Moderate blurring of the optic nerve head 3. Marked blurring of the optic nerve head 4. Optic Nerve head not visible

    Time frame: Day1/Baseline and Day180/Month 6

07

Results

Posted Jul 16, 2019

Participant flow

Double-Masked Period
Participant flow — Double-Masked Period
MilestoneDE-109 44 μgDE-109 440 μgDE-109 880 μg
Started208208176
Completed175162137
Not completed334639
Open-Label Period
Participant flow — Open-Label Period
MilestoneDE-109 44 μgDE-109 440 μgDE-109 880 μg
Started119102114
Completed635844
Not completed564470

Outcome measures

PrimaryThe Primary Endpoint, VH 0 Response, Was Defined as Having a VH Score of 0 at Month 5

At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Description VH score 0 = No inflammation

Time frame:
Day1 (Baseline) and Month 5 (Day150)
Reported as:
Count of participants · Participants
The Primary Endpoint, VH 0 Response, Was Defined as Having a VH Score of 0 at Month 5
ParticipantsDE-109 44 µgDE-109 440 µgDE-109 880 µg
The Primary Endpoint, VH 0 Response, Was Defined as Having a VH Score of 0 at Month 5284427
SecondaryVH 0 or 2-unit Response: Having a Reduction (Improvement) of at Least 2 Units From Baseline in VH Score or a VH Score of 0 at Month 5 (Modified SUN Scale)

At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Step Description 0 No inflammation 0.5+ Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex) 1. Mild blurring of the retinal vessels and optic nerve 1.5+ Optic nerve head and posterior retina view obstruction greater than 1+ but less than 2+ 2. Moderate blurring of the optic nerve head 3. Marked blurring of the optic nerve head 4. Optic Nerve head not visible

Time frame:
Day1/Baseline and Day150/Month 5
Reported as:
Count of participants · Participants
VH 0 or 2-unit Response: Having a Reduction (Improvement) of at Least 2 Units From Baseline in VH Score or a VH Score of 0 at Month 5 (Modified SUN Scale)
ParticipantsDE-109 44 µgDE-109 440 µgDE-109 880 µg
VH 0 or 2-unit Response: Having a Reduction (Improvement) of at Least 2 Units From Baseline in VH Score or a VH Score of 0 at Month 5 (Modified SUN Scale)435633
SecondaryVH 0 or 0.5+ Response: Having a VH Score of 0 or 0.5+ at Month 5 (Modified SUN Scale)

At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Description VH score 0.5+=Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex)

Time frame:
Day1/Baseline and Day150/Month 5
Reported as:
Count of participants · Participants
VH 0 or 0.5+ Response: Having a VH Score of 0 or 0.5+ at Month 5 (Modified SUN Scale)
ParticipantsDE-109 44 µgDE-109 440 µgDE-109 880 µg
VH 0 or 0.5+ Response: Having a VH Score of 0 or 0.5+ at Month 5 (Modified SUN Scale)8410470
Other pre-specifiedVH 0 Response at Month 6: Having a VH Score of 0 at Month 6 (Modified SUN Scale)

At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Description VH score 0 = No inflammation

Time frame:
Day1/Baseline and Day180/Month 6
Reported as:
Count of participants · Participants
VH 0 Response at Month 6: Having a VH Score of 0 at Month 6 (Modified SUN Scale)
ParticipantsDE-109 44 µgDE-109 440 µgDE-109 880 µg
VH 0 Response at Month 6: Having a VH Score of 0 at Month 6 (Modified SUN Scale)294351
Other pre-specifiedVH 0 or 2-unit Response at Month 6: Having a VH Score of 0 or a Decrease (Improvement) of at Least 2 Units From Baseline in VH Score at Month 6 (Modified SUN Scale)

At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Step Description 0 No inflammation 0.5+ Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex) 1. Mild blurring of the retinal vessels and optic nerve 1.5+ Optic nerve head and posterior retina view obstruction greater than 1+ but less than 2+ 2. Moderate blurring of the optic nerve head 3. Marked blurring of the optic nerve head 4. Optic Nerve head not visible

Time frame:
Day1/Baseline and Day180/Month 6
Reported as:
Count of participants · Participants
VH 0 or 2-unit Response at Month 6: Having a VH Score of 0 or a Decrease (Improvement) of at Least 2 Units From Baseline in VH Score at Month 6 (Modified SUN Scale)
ParticipantsDE-109 44 µgDE-109 440 µgDE-109 880 µg
VH 0 or 2-unit Response at Month 6: Having a VH Score of 0 or a Decrease (Improvement) of at Least 2 Units From Baseline in VH Score at Month 6 (Modified SUN Scale)425226
Other pre-specifiedVH 0 or 0.5+ Response at Month 6: Having a VH Score of 0 or 0.5+ at Month 6 (Modified SUNscale)

At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Step Description 0 No inflammation 0.5+ Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex) 1. Mild blurring of the retinal vessels and optic nerve 1.5+ Optic nerve head and posterior retina view obstruction greater than 1+ but less than 2+ 2. Moderate blurring of the optic nerve head 3. Marked blurring of the optic nerve head 4. Optic Nerve head not visible

Time frame:
Day1/Baseline and Day180/Month 6
Reported as:
Count of participants · Participants
VH 0 or 0.5+ Response at Month 6: Having a VH Score of 0 or 0.5+ at Month 6 (Modified SUNscale)
ParticipantsDE-109 44 µgDE-109 440 µgDE-109 880 µg
VH 0 or 0.5+ Response at Month 6: Having a VH Score of 0 or 0.5+ at Month 6 (Modified SUNscale)819066

Adverse events

Collected over Adverse events - begin capturing once the first treatment is given. Per Schedule of Events through study completion, up to 24 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DE-109 44 µg - Double Masked1/207 (0.5%)41/207 (19.8%)165/207 (79.7%)
DE-109 440 µg - Double Masked0/205 (0%)45/205 (22%)166/205 (81%)
DE-109 880 µg - Double Masked0/178 (0%)38/178 (21.3%)148/178 (83.1%)
DE-109 880 µg - Open-Label0/321 (0%)59/321 (18.4%)210/321 (65.4%)
Most frequent serious events
Showing 10 of 65
Most frequent serious events
EventDE-109 44 µg - Double MaskedDE-109 440 µg - Double MaskedDE-109 880 µg - Double MaskedDE-109 880 µg - Open-Label
UveitisEye disorders6/20710/20513/1785/321
Non-infectious endophthalmitisEye disorders0/2071/2057/17811/321
ChoroiditisEye disorders8/2074/2053/1786/321
Medication residueGeneral disorders2/2072/2054/1786/321
CataractEye disorders4/2072/2053/1784/321
Intermediate uveitisEye disorders0/2070/2053/1780/321
Intraocular pressure increasedInvestigations3/2073/2053/1783/321
Visual acuity reducedEye disorders1/2073/2050/1780/321
VitritisEye disorders2/2072/2050/1784/321
EndophthalmitisInfections and infestations0/2071/2051/1784/321
Most frequent other events
Showing 10 of 15
Most frequent other events
EventDE-109 44 µg - Double MaskedDE-109 440 µg - Double MaskedDE-109 880 µg - Double MaskedDE-109 880 µg - Open-Label
Intraocular pressure increasedInvestigations34/20734/20543/17844/321
IridocyclitisEye disorders31/20732/20530/17831/321
UveitisEye disorders19/20715/20529/17815/321
Conjunctival haemorrhageEye disorders22/20719/20526/17824/321
Eye painEye disorders18/20722/20519/17814/321
CataractEye disorders11/2078/20513/17832/321
Intermediate uveitisEye disorders16/20715/20514/1789/321
Cystoid macular oedemaEye disorders12/20715/20511/1787/321
Cataract subcapsularEye disorders3/20710/20512/17817/321
HeadacheNervous system disorders7/20712/2054/1787/321

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)DE-109 44 µgDE-109 440 µgDE-109 880 µgTotal
<=18 years0000
Between 18 and 65 years188191153532
>=65 years20172360
Sex: Female, Male
Sex: Female, Male(Participants)DE-109 44 µgDE-109 440 µgDE-109 880 µgTotal
Female113117113343
Male959163249
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DE-109 44 µgDE-109 440 µgDE-109 880 µgTotal
American Indian or Alaska Native4138
Asian767772225
Native Hawaiian or Other Pacific Islander1102
Black or African American16131342
White939979271
More than one race87318
Unknown or Not Reported1010626
Region of Enrollment
Region of Enrollment(Participants)DE-109 44 µgDE-109 440 µgDE-109 880 µgTotal
Colombia44513
Argentina20131043
United States707145186
Japan48618
United Kingdom48416
India696565199
Spain0123
Austria3205
Turkey4206
Brazil23510
Poland1326
Italy27211
Israel71311
Chile3249
France43714
Peru6101026
Germany55616
08

Study locations

151 sites
  • Phoenix, Arizona, United States
  • Tucson, Arizona, United States
  • Beverly Hills, California, United States
  • Loma Linda, California, United States
  • Los Angeles, California, United States
  • Mountain View, California, United States
  • Sacramento, California, United States
  • Torrance, California, United States
  • Aurora, Colorado, United States
  • Colorado Springs, Colorado, United States
  • Golden, Colorado, United States
  • Altamonte Springs, Florida, United States
  • Jacksonville, Florida, United States
  • Miami, Florida, United States
  • Orlando, Florida, United States
  • Pensacola, Florida, United States
  • Tampa, Florida, United States
  • Winter Haven, Florida, United States
  • Augusta, Georgia, United States
  • Chicago, Illinois, United States
  • Oak Park, Illinois, United States
  • Indianapolis, Indiana, United States
  • Iowa City, Iowa, United States
  • Wichita, Kansas, United States
  • Baltimore, Maryland, United States
  • Boston, Massachusetts, United States
  • Cambridge, Massachusetts, United States
  • Peabody, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Grand Rapids, Michigan, United States
  • Jackson, Michigan, United States
  • Royal Oak, Michigan, United States
  • Southfield, Michigan, United States
  • Edina, Minnesota, United States
  • Saint Louis, Missouri, United States
  • Missoula, Montana, United States
  • Lincoln, Nebraska, United States
  • Omaha, Nebraska, United States
  • Portsmouth, New Hampshire, United States
  • New Brunswick, New Jersey, United States
  • Newark, New Jersey, United States
  • Northfield, New Jersey, United States
  • Teaneck, New Jersey, United States
  • Toms River, New Jersey, United States
  • Albany, New York, United States
  • New York, New York, United States
  • Orchard Park, New York, United States
  • Rochester, New York, United States
  • Slingerlands, New York, United States
  • Southern Pines, North Carolina, United States
  • Winston-Salem, North Carolina, United States
  • Cleveland, Ohio, United States
  • Eugene, Oregon, United States
  • Camp Hill, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Reading, Pennsylvania, United States
  • West Mifflin, Pennsylvania, United States
  • Columbia, South Carolina, United States
  • Ladson, South Carolina, United States
  • Rapid City, South Dakota, United States
  • Knoxville, Tennessee, United States
  • Arlington, Texas, United States
  • Austin, Texas, United States
  • Dallas, Texas, United States
  • Fort Worth, Texas, United States
  • Houston, Texas, United States
  • McAllen, Texas, United States
  • San Antonio, Texas, United States
  • Salt Lake City, Utah, United States
  • Burlington, Vermont, United States
  • Richmond, Virginia, United States
  • Virginia Beach, Virginia, United States
  • Milwaukee, Wisconsin, United States
  • Buenos Aires, Argentina
  • Florencio Varela, Argentina
  • Mendoza, Argentina
  • Olivos, Argentina
  • Pilar, Argentina
  • Rosario, Argentina
  • Graz, Austria
  • Klagenfurt, Austria
  • Americana, Brazil
  • Araraquara, Brazil
  • Londrina, Brazil
  • Recife, Brazil
  • Rio de Janeiro, Brazil
  • Sao Paulo, Brazil
  • Sorocaba, Brazil
  • Santiago, Chile
  • Bogota, Colombia
  • Cali, Colombia
  • Floridablanca, Colombia
  • Medellin, Colombia
  • Marseille, France
  • Nantes, France
  • Paris, France
  • Berlin, Germany
  • Freiburg, Germany
  • Heidelberg, Germany

Showing the first 100 of 151 sites across 17 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Sep 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2019, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2011
First posted
May 23, 2011
Start
May 2011
Primary completionActual
Sep 2016
CompletionActual
Dec 2016
Results first posted
Jul 16, 2019
Last update
Jul 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01358266
Lead sponsor
Santen Inc.
Responsible party
Sponsor
First posted
May 23, 2011
Start date
May 2011
Primary completion
Sep 2016
Completion
Dec 2016
Results posted
Jul 16, 2019
Last update
Jul 16, 2019

Study contacts

Abu Abraham, MD
study director · Santen Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion